Further research is recommended to investigate if circulating IGF1 and IGFBP3 levels can be used to identify people at high risk of colorectal cancer and to explore potential lifestyle or pharmaceutical ways to lower IGF1 bioactivity as a risk reduction strategy targeting high-risk individuals. The gene discussed is IGFBP3; the disease is colorectal cancer.